Table 3 Adverse events associated with IVIG + anakinra treatment in MIS-C patients
Adverse event | IVIG monotherapy (n = 14) | IVIG + anakinra without CS (n = 25) | IVIG + anakinra with CS (n = 9) | p-value |
|---|---|---|---|---|
Elevated LFTs (n %) | 2, 14% | 6, 24% | 7, 67% | 0.008* |
Neutropenia (n %) | 1, 7% | 5, 20% | 3, 33% | 0.36 |
Hemolytic anemia (n %) | 1, 7% | 1, 4% | 1, 11% | 0.73 |
Anaphylaxis (n %) | 0, 0% | 0, 0% | 0, 0% | N/A |
Rash (n %) | 0, 0% | 2, 8% | 0, 0% | 0.42 |
Re-hospitalization (n %) | 0, 0% | 0, 0% | 0, 0% | N/A |